CME / ABIM MOC / CE

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Authors: Tina Cascone, MD, PhD; Angel Qin, MD; Pamela P. Samson, MD; Erin Schenk, MD, PhD; Brendon M. Stiles, MD; Heather Wakelee, MD, FASCO
CME / ABIM MOC / CE Released: 5/2/2024
Valid for credit through: 3/1/2025, 11:59 PM EST

Credits Available

Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.25 ABIM MOC points

Nurses - 1.25 ANCC Contact Hour(s) (0.75 contact hours are in the area of pharmacology)

Pharmacists - 1.25 Knowledge-based ACPE (0.125 CEUs)

IPCE - 1.25 Interprofessional Continuing Education (IPCE) credit 

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, pulmonologists, pathologists, radiologists, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the management of patients with lung cancer.

The goal of this activity is for learners to be better able to recognize multi-modal treatment options for patients with early-stage or locally advanced NSCLC.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data evaluating treatment approaches for patients with early-stage or locally advanced NSCLC
Have greater competence related to
- Tailoring treatment decisions for patients with early-stage and locally advanced NSCLC
- Mitigating adverse events in patients being treated for early-stage or locally advanced NSCLC
Demonstrate greater confidence in their ability to
- Coordinate with other members of the multidisciplinary team to optimize outcomes for patients with early-stage or locally advanced NSCLC

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Tina Cascone, MD, PhD

Faculty
Graduate School of Biomedical Sciences
Assistant Professor
Department of Thoracic-Head & Neck Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Tina Cascone, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Arrowhead Pharmaceuticals, Inc.; AstraZeneca; Bristol Myers Squibb Company; Genentech; Merck; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.
Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb Company; Roche
Research funding from: AstraZeneca; Bristol Myers Squibb Company; EMD Serono, Inc.

Angel Qin, MD

Clinical Assistant Professor
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Disclosures

Angel Qin, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.
Research funding from: AstraZeneca; Clovis Oncology; Genentech; Janssen; Merck; Xencor, Inc.

Pamela P. Samson, MD

Assistant Professor of Radiation Oncology
Siteman Cancer Center
Washington University in St Louis
St Louis, Missouri

Disclosures

Pamela P. Samson, MD, has the following relevant financial relationships:
Speaker or member of speakers bureau for: Varian Medical Systems, Inc.

Erin Schenk, MD, PhD

Assistant Professor of Medicine
University of Colorado
Aurora, Colorado

Disclosures

Erin Schenk, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Actinium Pharmaceuticals, Inc.(former); AstraZeneca (former); BioAtla Inc. (former); G1 Therapeutics, Inc. (former); Prescient Advisory (former); Regeneron Pharmaceuticals, Inc. (former); Within3 (former)
Speaker or member of speakers bureau for: BeiGeineius (former); Janssen (former); MJH Life Sciences (former); Regeneron Pharmaceuticals, Inc. (former); Sanofi (former)

Brendon M. Stiles, MD

Professor and Chief, Thoracic Surgery and Surgical Oncology
Albert Einstein College of Medicine and Montefiore Medical Center
New York, New York

Disclosures

Brendon M. Stiles, MD, has the following relevant financial relationships:
Consultant or advisor for: Arcus Biosciences; AstraZeneca; Bristol Myers Squibb Company; Galvanize Therapeutics; Genentech; Medtronic, Inc.; Merck; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Roche
Research funding from: Bristol Myers Squibb Foundation

Heather Wakelee, MD, FASCO

Professor of Medicine and Chief
Division of Oncology
Stanford University School of Medicine
Deputy Director, Stanford Cancer Institute
Past President, International Association for the Study of Lung Cancer (IASLC)
Palo Alto, California

Disclosures

Heather Wakelee, MD, FASCO, has the following relevant financial relationships:
Consultant or advisor for: Genentech; Merck; Mirati Therapeutics, Inc. (former); Roche
Research funding from: AstraZeneca; Bayer; Bristol Myers Squibb Company; Clovis Oncology; Genentech; Helsinn Therapeutics, Inc.; Merck; Roche; Seagen, Inc.; Xcovery Vision

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Formerly employed by an ineligible company: Medtronic, Inc.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For Nurses

Awarded 1.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) (Universal Activity Number: JA0007105-0000-24-150-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Authors: Tina Cascone, MD, PhD; Angel Qin, MD; Pamela P. Samson, MD; Erin Schenk, MD, PhD; Brendon M. Stiles, MD; Heather Wakelee, MD, FASCOFaculty and Disclosures

CME / ABIM MOC / CE Released: 5/2/2024

Valid for credit through: 3/1/2025, 11:59 PM EST

processing....

Contents of This Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Unresectable Stage III Non-Small Cell Lung Cancer

Join Dr Pamela Samson as she navigates the complexities of managing unresectable stage III cancer in this enlightening presentation.
Pamela P. Samson, MD

Adjuvant Immunotherapy

Dr Schenk delves into the realm of adjuvant immunotherapy, offering insights that could reshape treatment strategies.
Erin Schenk, MD, PhD

Neoadjuvant Immunotherapy

Explore the frontier of neoadjuvant immunotherapy with Dr Qin and uncover its potential impact on patient outcomes.
Angel Qin, MD

Periadjuvant (Perioperative) Immunotherapy

Discover the latest advancements in perioperative immunotherapy with Dr Heather Wakelee.
Heather Wakelee, MD, FASCO

Surgery in the Immunotherapy Era

Join Dr Stiles as he discusses the evolving landscape of surgery in the era of immunotherapy, offering a glimpse into the future of surgical oncology.
Brendon Stiles, MD

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

Page 1 of 8

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Tina Cascone, MD, PhD

Angel Qin, MD

Pamela P. Samson, MD

Erin Schenk, MD, PhD

Brendon M. Stiles, MD

Heather Wakelee, MD, FASCO

Editor

John Churchwell, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Tina Cascone, MD, PhD

Angel Qin, MD

Pamela P. Samson, MD

Erin Schenk, MD, PhD

Brendon M. Stiles, MD

Heather Wakelee, MD, FASCO

Editor

John Churchwell, PhD

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Early-Stage and Locally Advanced Non-Small Cell Lung Cancer Management

Contents of This Activity

Unresectable Stage III Non-Small Cell Lung Cancer

Adjuvant Immunotherapy

Neoadjuvant Immunotherapy

Periadjuvant (Perioperative) Immunotherapy

Surgery in the Immunotherapy Era

Learning Feedback Questions